Is This Decision by Pfizer Bad News for Eli Lilly?

Eli Lilly (NYSE: LLY) stock has soared by double digits over the past year — and for good reason. The pharma giant sells two of the most sought-after drugs today, weight loss treatments Mounjaro and Zepbound. Together, these drugs are adding billions of dollars to the company’s

admin